Cargando…

International consensus on quality standards for brain health-focused care in multiple sclerosis

BACKGROUND: Time matters in multiple sclerosis (MS). Irreversible neural damage and cell loss occur from disease onset. The MS community has endorsed a management strategy of prompt diagnosis, timely intervention and regular proactive monitoring of treatment effectiveness and disease activity to imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hobart, Jeremy, Bowen, Amy, Pepper, George, Crofts, Harriet, Eberhard, Lucy, Berger, Thomas, Boyko, Alexey, Boz, Cavit, Butzkueven, Helmut, Celius, Elisabeth Gulowsen, Drulovic, Jelena, Flores, José, Horáková, Dana, Lebrun-Frénay, Christine, Marrie, Ruth Ann, Overell, James, Piehl, Fredrik, Rasmussen, Peter Vestergaard, Sá, Maria José, Sîrbu, Carmen-Adella, Skromne, Eli, Torkildsen, Øivind, van Pesch, Vincent, Vollmer, Timothy, Zakaria, Magd, Ziemssen, Tjalf, Giovannoni, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826858/ https://www.ncbi.nlm.nih.gov/pubmed/30381987 http://dx.doi.org/10.1177/1352458518809326

Ejemplares similares

Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool
por: Hobart, Jeremy, et al.
Publicado: (2022)

The importance of collecting structured clinical information on multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments
por: Torkildsen, Øivind, et al.
Publicado: (2014)

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Dysembryoplastic neuroepithelial tumor and probable sudden unexplained death in epilepsy: a case report
por: Sîrbu, Carmen-Adella
Publicado: (2011)

Serum markers of multiple sclerosis - a new approach
por: Torkildsen, Øivind
Publicado: (2021)

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
por: Klistorner, Alexander, et al.
Publicado: (2018)

Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy
por: Eid, Karine, et al.
Publicado: (2022)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Determinants of disability development in patients with multiple sclerosis
por: Kara, Fatma, et al.
Publicado: (2021)

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome
por: Meyniel, Claire, et al.
Publicado: (2012)

Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients
por: Boz, Cavit, et al.
Publicado: (2003)

Month of birth and risk of multiple sclerosis: confounding and adjustments
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Optimizing treatment success in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Cognition and its relation to brain health in patients with MS: Response to letter
por: Hobart, Jeremy, et al.
Publicado: (2020)

Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab
por: Holmøy, Trygve, et al.
Publicado: (2018)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
por: Barnett, Michael, et al.
Publicado: (2021)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Bone Turnover and Metabolism in Patients with Early Multiple Sclerosis and Prevalent Bone Mass Deficit: A Population-Based Case-Control Study
por: Moen, Stine Marit, et al.
Publicado: (2012)

The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis
por: Simonsen, Cecilia Smith, et al.
Publicado: (2020)

Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS)
por: Tsivgoulis, Georgios, et al.
Publicado: (2022)

Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS
por: Torkildsen, Øivind, et al.
Publicado: (2014)

Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey
por: Usta, Nuray Can, et al.
Publicado: (2022)

Interdisziplinäre Kommunikation: Augenarztbriefe an diabetologische Schwerpunktpraxen (DSP)
por: Stock, Lydia, et al.
Publicado: (2020)

Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
por: Simonsen, Cecilia Smith, et al.
Publicado: (2016)

High prevalence of fatigue in contemporary patients with multiple sclerosis
por: Broch, Line, et al.
Publicado: (2021)

Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
por: Simonsen, Cecilia Smith, et al.
Publicado: (2022)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures
por: Paucke, Madlen, et al.
Publicado: (2018)

Spectral Analysis of Heart Rate Variability: Time Window Matters
por: Li, Kai, et al.
Publicado: (2019)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kfa3cqn382feb7o8hasmikre5b